Kidney Cancer Coverage from Every Angle

Thomas Powles, MD, PhD: A Look Into the Future of Kidney Cancer Treatment

Posted: Tuesday, February 16, 2021

Thomas Powles, MD, PhD, of Queen Mary, University of London, discusses the current and future landscape of kidney cancer treatment, including the many front-line treatment choices (most notably combinations of VEGF tyrosine kinase and immune checkpoint inhibitors); issues in second-line disease; HIF inhibitors and everolimus; circulating biomarkers; molecular classification of subgroups of patients; and the potential for immune checkpoint inhibitors to improve survival postoperatively.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.